# US 9,433,613 B2 · Compositions and methods for treating bacterial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,433,613 B2
- Document ID: US9433613B2
- Status: Granted
- Kind: B2
- Application number: 14/442,135
- Filed: 2014-01-13
- Published: 2016-02-18
- Granted: 2016-09-06
- Earliest claimed: 2013-01-14
- Assignees: Wockhardt Limited
- Applicants: Wockhardt Limited
- Inventors: Mahesh Vithalbhai Patel; Sachin Bhagwat; Prasad Keshav Deshpande
- Web page: https://patentgrep.com/patent/US9433613B2

## CPC

- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Pharmaceutical compositions and methods for treating bacterial infections are disclosed.

## Claims

### Claim 1

A pharmaceutical composition comprising: (a) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof, and (b) an enhancer compound or a pharmaceutically acceptable derivative thereof; wherein the enhancer compound is trans-(2S,5R)-sulfuric acid mono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazino carbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl] ester.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the antibacterial agent is selected from a group consisting of aminoglycosides, ansamycins, carbacephems, penems, carbapenems, cephalosporins, cephamycins, lincosamides, lipopeptides, macrolides, monobactams, nitrofurans, penicillins, polypeptides, quinolones, sulfonamides, tetracyclines, and oxazolidinone antibacterial agents.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the enhancer compound or pharmaceutically acceptable derivative thereof is present at an amount of from about 0.01 to 10 gm per gram of the antibacterial agent or pharmaceutically acceptable derivative thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the enhancer compound or pharmaceutically acceptable derivative thereof is capable of selectively binding to one or more essential penicillin binding proteins (PBPs).

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the antibacterial agent or pharmaceutically acceptable derivative thereof, and the enhancer compound or pharmaceutically acceptable derivative thereof are complementary penicillin binding protein (PBP) binding agents.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the enhancer compound or pharmaceutically acceptable derivative thereof, and the antibacterial agent or pharmaceutically acceptable derivative thereof are present in concentrations lower than, or equal to, or higher than corresponding minimum inhibitory concentrations.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the antibacterial agent or pharmaceutically acceptable derivative thereof is present at its minimum filamentation concentration, and the enhancer compound or pharmaceutically acceptable derivative thereof is present at its minimum spheroplasting concentration.